Novo Nordisk A/S (NVO:NYSE) closed at $39.05 on October 23, 2026, down 0.96% on the day. The stock trades 39.1% below its 52-week high of $64.16 and 11.2% above its 52-week low of $35.12. Over the past year, it lost 26.3%. Novo Nordisk A/S is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, NVO closed higher on 116 days (46%). Its best day was February 6, 2026 (+9.92%) and its worst was February 23, 2026 (-16.43%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 2 times.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Find more stocks like NVO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.